The great links just keep coming, so enjoy an extra edition of the Biotech Reading List while you await the return of the Tweets of the Week on Friday September 4!
Strategies to enhance patient responses to checkpoint inhibitors
Garrett Rhyasen (Oncology Discovery)
Clinical Trials: Getting Much Worse, or Much Better?
Derek Lowe (In the Pipeline)
The Art Of The In-License
Michael Gilman (LifeSciVC)
Costs of Care and Shared Decision Making: The Value of Knowing
Ethan Weiss (Somewhere North of 140 Characters)
Hot Lines, Simultaneous Publications, And The Decline Of Medical Meetings
Larry Husten (CardioBrief)
Why Too Many Clinical Trials Fail -- And A Simple Solution That Could Increase Returns On Pharma R&D
David Grainger (Forbes)
Precision medicine, linked to DNA, still too often misses
Sharon Begley (Stat News / Boston Globe)
Garrett Rhyasen (Oncology Discovery)
Clinical Trials: Getting Much Worse, or Much Better?
Derek Lowe (In the Pipeline)
The Art Of The In-License
Michael Gilman (LifeSciVC)
Costs of Care and Shared Decision Making: The Value of Knowing
Ethan Weiss (Somewhere North of 140 Characters)
Hot Lines, Simultaneous Publications, And The Decline Of Medical Meetings
Larry Husten (CardioBrief)
Why Too Many Clinical Trials Fail -- And A Simple Solution That Could Increase Returns On Pharma R&D
David Grainger (Forbes)
Precision medicine, linked to DNA, still too often misses
Sharon Begley (Stat News / Boston Globe)
RSS Feed
